This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Thursday's Top 10 Articles, Videos on TheStreet

Stocks in this article: SEAC COMV BAC

NEW YORK ( TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.

Data-Based IPOs: Splunk, Infoblox, Proofpoint
Debra Borchardt
It's California dreaming for these three data-based IPOs with Splunk looking the strongest.

5 Stocks Insiders Love Right Now
Roberto Pedone
Insiders at these companies have been scooping up shares of their own stock lately. (Stocks mentioned include: SEAC, COMV)

Windows Trips Up H-P's Giant 'iPad' Bet
Jonathan Blum
The HP TouchSmart 9300 PC puts iPad-like touch on your desktop. But it's still too much Microsoft, too little Apple.

Stocks Hold Gains After Mixed Economic Data
Andrea Tse
Wall Street wavers after a smooth Spanish bond auction and a solid round of earnings reports is followed by a series of mixed economic indicators.

Thursday's Earnings Roundup: BAC, MS, DD, TRV, DHR, VZ, EMC, NOK
Alexandra Zendrian
These companies reported earnings on Thursday before the bell.

EMC Profit Climbs on Cloud, Big Data
James Rogers
Shrugging off recent tech sector unease, EMC reports solid first-quarter results.

Qualcomm's Pain May Be Apple's Gain
Chris Ciaccia
Qualcomm said supply of some of its chips aren't able to keep up with demand, which likely indicates Apple continues to do exceptionally well.

Molycorp Inc. Stock Upgraded (MCP)
TheStreet Wire
Molycorp (NYSE:MCP) has been upgraded by TheStreet Ratings from a sell to hold.

Bank of America Beats Estimates in Noisy Quarter (Update 2)
Dan Freed
Legacy mortgage issues continue to weigh.

Human Genome Rejects $2.6B Bid From GlaxoSmithKline (Update 1)
Adam Feuerstein
Human Genome Sciences rejects a $2.6 billion unsolicited offer from GlaxoSmithKline.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs